Xinjiang Bai Hua Cun Pharma TechLtd Past Earnings Performance
Past criteria checks 2/6
Xinjiang Bai Hua Cun Pharma TechLtd has been growing earnings at an average annual rate of 61.6%, while the Pharmaceuticals industry saw earnings growing at 9.2% annually. Revenues have been growing at an average rate of 10.2% per year. Xinjiang Bai Hua Cun Pharma TechLtd's return on equity is 3.7%, and it has net margins of 7%.
Key information
61.6%
Earnings growth rate
60.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 10.2% |
| Return on equity | 3.7% |
| Net Margin | 7.0% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Xinjiang Bai Hua Cun Pharma TechLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 384 | 27 | 75 | 32 |
| 31 Dec 23 | 369 | 13 | 77 | 32 |
| 30 Sep 23 | 359 | -28 | 97 | 31 |
| 30 Jun 23 | 353 | -32 | 103 | 30 |
| 31 Mar 23 | 367 | -29 | 97 | 29 |
| 31 Dec 22 | 350 | -35 | 95 | 27 |
| 30 Sep 22 | 353 | 16 | 85 | 19 |
| 30 Jun 22 | 325 | 20 | 77 | 14 |
| 31 Mar 22 | 293 | 60 | 75 | 8 |
| 31 Dec 21 | 281 | 60 | 73 | 5 |
| 30 Sep 21 | 187 | -223 | 62 | 9 |
| 30 Jun 21 | 105 | -233 | 61 | 8 |
| 31 Mar 21 | 85 | -320 | 58 | 7 |
| 31 Dec 20 | 85 | -320 | 63 | 6 |
| 30 Sep 20 | 141 | -57 | 84 | 0 |
| 30 Jun 20 | 228 | -40 | 90 | 0 |
| 31 Mar 20 | 238 | 9 | 93 | 0 |
| 31 Dec 19 | 262 | 34 | 88 | 0 |
| 30 Sep 19 | 261 | -696 | 83 | 0 |
| 30 Jun 19 | 332 | -691 | 81 | 0 |
| 31 Mar 19 | 378 | -680 | 81 | 0 |
| 31 Dec 18 | 419 | -675 | 76 | 0 |
| 30 Sep 18 | 457 | -564 | 62 | 0 |
| 30 Jun 18 | 381 | -555 | 57 | 0 |
| 31 Mar 18 | 382 | -552 | 51 | 0 |
| 31 Dec 17 | 420 | -564 | 49 | 0 |
| 30 Sep 17 | 653 | 103 | 38 | 0 |
| 30 Jun 17 | 715 | 328 | 61 | 0 |
| 31 Mar 17 | 784 | 224 | 84 | 0 |
| 31 Dec 16 | 745 | 139 | 113 | 0 |
| 30 Sep 16 | 708 | -125 | 188 | 0 |
| 30 Jun 16 | 748 | -433 | 188 | 0 |
| 31 Mar 16 | 780 | -419 | 202 | 0 |
| 31 Dec 15 | 809 | -406 | 220 | 0 |
| 30 Sep 15 | 910 | -268 | 240 | 0 |
| 30 Jun 15 | 1,022 | -300 | 253 | 0 |
| 31 Mar 15 | 1,058 | -276 | 239 | 0 |
| 31 Dec 14 | 1,109 | -234 | 216 | 0 |
| 30 Sep 14 | 1,093 | -116 | 142 | 0 |
| 30 Jun 14 | 1,115 | -54 | 136 | 0 |
| 31 Mar 14 | 1,105 | 7 | 145 | 0 |
| 31 Dec 13 | 1,235 | 2 | 156 | 0 |
| 30 Sep 13 | 1,193 | -3 | 174 | 0 |
| 30 Jun 13 | 1,121 | 16 | 175 | 0 |
Quality Earnings: 600721 has a large one-off loss of CN¥45.0M impacting its last 12 months of financial results to 31st March, 2024.
Growing Profit Margin: 600721 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 600721 has become profitable over the past 5 years, growing earnings by 61.6% per year.
Accelerating Growth: 600721 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 600721 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-1.5%).
Return on Equity
High ROE: 600721's Return on Equity (3.7%) is considered low.